DOJ moves medical cannabis to Schedule III; biotech firms eye funding and IPOs amid banking and tax uncertainty.

By Puyaan Singh and Christy Santhosh April 30 (Reuters) - Companies developing cannabis-based medicines say U.S. moves to ...

Following the recent drug rescheduling from the Trump Administration, medicinal marijuana companies are preparing to ...

Legal rules around medical marijuana have been loosened, following an April 23 order from the Acting U.S. Attorney General ...

Researchers at Johns Hopkins and UC San Diego used artificial intelligence to analyze comments in the public record ...

The federal government’s reclassification of medical marijuana products as Schedule III drugs doesn’t federally legalize marijuana, but it might extend tax breaks to some cannabis businesses. The ...

Johns Hopkins research underscores the increased risks of combining cannabis edibles and alcohol—key for public health ...

When the U.S. Department of Justice moved to reclassify medical marijuana to a Schedule III drug on April 23, 2026, it set ...

Possessing marijuana is a federal crime punishable by fines and prison time. Selling or cultivating marijuana is a more ...

In April, the Department of Justice and the Drug Enforcement Administration took a major step forward in medical cannabis.

The move should make it easier for researchers to study the substance and give tax breaks to licensed medical marijuana ...

Charlotte Caldwell’s campaign to access legal cannabis oil for severely epileptic son Billy led to historic law change in ...